Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Pila Pharma AB's Enterprise Value for the quarter that ended in Dec. 2025 was €6.38 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pila Pharma AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pila Pharma AB EV-to-EBIT Related Terms
Pila Pharma AB EV-to-EBIT Historical Data
* Premium members only.
The historical data trend for Pila Pharma AB's EV-to-EBIT can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5KC vs VRTX, REGN, RVMD: EV-to-EBIT Comparison
For the Biotechnology subindustry, Pila Pharma AB's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pila Pharma AB EV-to-EBIT vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pila Pharma AB's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Pila Pharma AB's EV-to-EBIT falls into.
Pila Pharma AB's current Enterprise Value is €5.12 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Pila Pharma AB's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was €-1.53 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pila Pharma AB (FRA:5KC) has a EV-to-EBIT of -3.36 as of Aug. 10, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pila Pharma AB and its competitors. According to the industry distribution chart, Pila Pharma AB ranks #999999 out of 370 companies in the Biotechnology industry.
Is Pila Pharma AB's EV-to-EBIT too high?
Pila Pharma AB's current EV-to-EBIT is -3.36. Based on the distribution chart, Pila Pharma AB ranks #999999 out of 370 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Pila Pharma AB has a GF Score™ of 50/100, reflecting its overall financial health beyond just this single metric.
How does Pila Pharma AB's EV-to-EBIT compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Pila Pharma AB ranks #999999 out of 370 companies for EV-to-EBIT. This places Pila Pharma AB in the lower half of its industry. The industry median EV-to-EBIT is 15.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Biotechnology company?
The median EV-to-EBIT among Biotechnology companies is 15.03, based on 370 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Pila Pharma AB and its competitors. For the Biotechnology industry, the median EV-to-EBIT is 15.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Pila Pharma AB's current EV-to-EBIT is -3.36. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pila Pharma AB stock overvalued right now?
Pila Pharma AB (FRA:5KC) has a current EV-to-EBIT of -3.36. The stock's GF Value™ is €0.16, compared to a current price of €0.11 — trading 30% below its estimated fair value. The current EV-to-EBIT is -3.36. Pila Pharma AB's overall GF Score™ is 50/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Pila Pharma AB (FRA:5KC), the current EV-to-EBIT is -3.36 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Pila Pharma AB (FRA:5KC) Overvalued in 2026?
Based on GuruFocus' analysis, Pila Pharma AB stock appears to be undervalued.
The current stock price of €0.11 is trading 30% below its estimated GF Value™ of €0.16.
Key valuation signals for FRA:5KC:
EV-to-EBIT: -3.36
GF Value™: €0.16 vs. price of €0.11 (30% below fair value)
No single metric tells the full story. See the FRA:5KC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Pila Pharma AB is a clinical stage pharmaceutical company. It is developing a TRPV1 antagonist, XEN-D0501, as a novel type of oral anti-diabetic agent.
50GF Score
Get the complete analysis for FRA:5KC
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5KC has been successfully added to your 
